A balancing view: Lifetime channeling of infliximab for Crohn's disease

American Journal of Gastroenterology

Volumn 100, Issue 7, 2005, Pages 1438-1439

  Hanauer, Stephen B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; CROHN DISEASE; DRUG SAFETY; ENTEROCUTANEOUS FISTULA; HEALTH ECONOMICS; HUMAN; IMMUNOGENICITY; LONG TERM CARE; PRIORITY JOURNAL; RECTOVAGINAL FISTULA; REMISSION; RHEUMATOID ARTHRITIS; SHORT SURVEY; ARTICLE; DRUG ADMINISTRATION; EVALUATION;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL AGENTS; HUMANS;

EID: 22744435288     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.50622_3.x     Document Type: Short Survey

References (4)

1. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
2. Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission under treatment is associated with a high risk of relapse [abstract]. Gastroenterology 2004;126:A-113.
3. Faubion WA, Jr., Loftus EV, Jr., Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001;121:255-60.
4. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease [In Process Citation]. Gastroenterology 2000;119:895-902.